This site is intended for healthcare professionals
Drug news

VA 106483 (fedovapagon) meets primary endpoint in EQUINOC Phase III trial for nocturia in men with benign prostatic hyperplasia.- Vantia Therapeutics.

Read time: 1 mins
Last updated:4th Oct 2017
Published:4th Oct 2017
Source: Pharmawand
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest